Display options
Cite
Mazdeh M, Hosseini S, Taheri M, et al. The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study. Clin Transl Med. 2018;7(1):38doi: 10.1186/s40169-018-0216-3.
Mazdeh, M., Hosseini, S., Taheri, M., & Ghafouri-Fard, S. (2018). The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study. Clinical and translational medicine, 7(1), 38. https://doi.org/10.1186/s40169-018-0216-3
Mazdeh, Mehrdokht, et al. "The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study." Clinical and translational medicine vol. 7,1 (2018): 38. doi: https://doi.org/10.1186/s40169-018-0216-3
Mazdeh M, Hosseini S, Taheri M, Ghafouri-Fard S. The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study. Clin Transl Med. 2018 Nov 30;7(1):38. doi: 10.1186/s40169-018-0216-3. PMID: 30498920; PMCID: PMC6265353.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Med. 2018 Nov 30;7(1):38. doi: 10.1186/s40169-018-0216-3.

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study.

Clinical and translational medicine

Mehrdokht Mazdeh, Shno Hosseini, Mohammad Taheri, Soudeh Ghafouri-Fard

Affiliations

  1. Department of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran.
  2. Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
  3. Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].
  4. Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].
  5. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].

PMID: 30498920 PMCID: PMC6265353 DOI: 10.1186/s40169-018-0216-3

Abstract

Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved for treatment of relapsing forms of MS. This study aims at determining the effect of natalizumab on expanded disability status scale (EDSS) score and relapse rate of MS patients. Fifty MS patients participated in the present prospective cohort study. Twenty patients (Mean age ± SD: 33 ± 6.03) received natalizumab and 30 patients (Mean age ± SD: 36.83 ± 7.24) were under treatment with IFN-β (control group). Patients were followed-up during a 12-month period. EDSS score and clinical signs were assessed monthly. Significant decreases were detected in EDSS score in natalizumab treated patients compared with the controls in months 10, 11 and 12. EDSS score showed a significant decrease in 80% of natalizumab treated patients. Number of relapses was significantly lower in natalizumab treated patients compared with control group. Natalizumab is effective in improvement of disability and reduction of relapse rate in MS patients.

Keywords: EDSS; Multiple sclerosis; Natalizumab; Relapse

References

  1. N Engl J Med. 2003 Jan 2;348(1):15-23 - PubMed
  2. Nature. 1992 Mar 5;356(6364):63-6 - PubMed
  3. Neurology. 2005 Apr 26;64(8):1336-42 - PubMed
  4. Ann Neurol. 2005 Dec;58(6):840-6 - PubMed
  5. N Engl J Med. 2006 Mar 2;354(9):899-910 - PubMed
  6. N Engl J Med. 2006 Mar 2;354(9):911-23 - PubMed
  7. Arq Neuropsiquiatr. 2015 Sep;73(9):736-40 - PubMed
  8. Neuropsychiatr Dis Treat. 2017 Jun 28;13:1691-1702 - PubMed
  9. J Immunol. 1986 Sep 15;137(6):1893-6 - PubMed
  10. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):923-7 - PubMed
  11. J Allergy Clin Immunol. 1996 Dec;98(6 Pt 2):S270-7 - PubMed

Publication Types